Coronavirus Update: More Companies Join Therapeutics Accelerator, FDA Delays AdCom For First NASH Drug
Healios Joins Search For Acute Respiratory Distress Syndrome Treatment
As the global number of COVID-19 cases exceeds 500,000 for the first time, more biopharma companies throw their weight behind Gates Foundation's drug-hunting initiative.
You may also be interested in...
Private Company Edition: Neogene, Escient, ESCAPE, Resolution and Attralus raised a combined $320m in venture capital rounds. Also, large Recursion round could double the size of its pipeline, Korro Bio raised $91.5m and Flagship launched Generate Biomedicines.
The lockdowns caused by coronavirus has led to significant decline of multiple sclerosis patients getting to see neurologists and getting treatment. It has also reduced the number of treatment switches and Merck's drug Mavenclad is suffering as a consequence.
Company expects clinical trials to begin by September and says first batches could be available for emergency use authorization in early 2021; J&J pledges vaccine will be available to public on not-for-profit basis.